Abstract
Low toxicity, oncospecificity, immunogenicity and relatively frequent expression of CT antigens in many types of cancer justify their use in cancer immunotherapy. This review presents the data on CTA use in new clinical approaches to the malignant process control, developed from the ideas of the anti-tumor immunity mechanisms. In particular, we highlight the results of application of immune checkpoint inhibitors, external correction of the immune response by vaccination with ex vivo generated dendritic cells, natural killer cells and T-lymphocytes; induction and synchronization of CTA expression with DNA hypomethylating agents to enhance the immunogenicity of cancer cells, etc. As a result, we demonstrate the need for rethinking current clinical strategies in terms of the choice of chemotherapeutic agents and immunotherapy design, which will significantly increase the effectiveness of cancer treatment.
Highlights
Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., Phan G.Q., Hughes M.S., Kammula U.S, Miller A.D., Hessman C.J., Stewart A.A., Restifo N.P., Quezado M.M., Alimchandani M., Rosenberg A.Z., Nath A., Wang T., Bielekova B., Wuest S.C., Akula N., McMahon F.J., Wilde S., Mosetter B., Schendel D.J., Laurencot C.M., Rosenberg S.A. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
Oncospecificity, immunogenicity and relatively frequent expression of CT antigens in many types of cancer justify their use in cancer immunotherapy
This review presents the data on CTA use in new clinical approaches to the malignant process control, developed from the ideas of the anti-tumor immunity mechanisms
Summary
Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., Phan G.Q., Hughes M.S., Kammula U.S, Miller A.D., Hessman C.J., Stewart A.A., Restifo N.P., Quezado M.M., Alimchandani M., Rosenberg A.Z., Nath A., Wang T., Bielekova B., Wuest S.C., Akula N., McMahon F.J., Wilde S., Mosetter B., Schendel D.J., Laurencot C.M., Rosenberg S.A. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Clinical cancer research: an official journal of the American Association for Cancer Research.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
